CA2779282C - Methods and nutritional formulations to increase the efficacy and reduce the side effects of cancer treatment - Google Patents
Methods and nutritional formulations to increase the efficacy and reduce the side effects of cancer treatment Download PDFInfo
- Publication number
- CA2779282C CA2779282C CA2779282A CA2779282A CA2779282C CA 2779282 C CA2779282 C CA 2779282C CA 2779282 A CA2779282 A CA 2779282A CA 2779282 A CA2779282 A CA 2779282A CA 2779282 C CA2779282 C CA 2779282C
- Authority
- CA
- Canada
- Prior art keywords
- patient
- cancer
- diet
- fasting
- chemotherapy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- G—PHYSICS
- G06—COMPUTING OR CALCULATING; COUNTING
- G06Q—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES; SYSTEMS OR METHODS SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES, NOT OTHERWISE PROVIDED FOR
- G06Q10/00—Administration; Management
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L13/00—Meat products; Meat meal; Preparation or treatment thereof
- A23L13/60—Comminuted or emulsified meat products, e.g. sausages; Reformed meat from comminuted meat product
- A23L13/65—Sausages
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23P—SHAPING OR WORKING OF FOODSTUFFS, NOT FULLY COVERED BY A SINGLE OTHER SUBCLASS
- A23P20/00—Coating of foodstuffs; Coatings therefor; Making laminated, multi-layered, stuffed or hollow foodstuffs
- A23P20/20—Making of laminated, multi-layered, stuffed or hollow foodstuffs, e.g. by wrapping in preformed edible dough sheets or in edible food containers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/07—Retinol compounds, e.g. vitamin A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Polymers & Plastics (AREA)
- Business, Economics & Management (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Operations Research (AREA)
- Entrepreneurship & Innovation (AREA)
- Quality & Reliability (AREA)
- Strategic Management (AREA)
- Tourism & Hospitality (AREA)
- Physics & Mathematics (AREA)
- General Business, Economics & Management (AREA)
- General Physics & Mathematics (AREA)
- Theoretical Computer Science (AREA)
- Human Resources & Organizations (AREA)
- Marketing (AREA)
- Economics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Diabetes (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US25415409P | 2009-10-22 | 2009-10-22 | |
| US61/254,154 | 2009-10-22 | ||
| PCT/US2010/053821 WO2011050302A2 (en) | 2009-10-22 | 2010-10-22 | Methods and nutritional formulations to increase the efficacy and reduce the side effects of cancer treatment |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2779282A1 CA2779282A1 (en) | 2011-04-28 |
| CA2779282C true CA2779282C (en) | 2017-12-05 |
Family
ID=43900993
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2779282A Active CA2779282C (en) | 2009-10-22 | 2010-10-22 | Methods and nutritional formulations to increase the efficacy and reduce the side effects of cancer treatment |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US20110118528A1 (https=) |
| EP (1) | EP2490684B1 (https=) |
| JP (1) | JP2013508411A (https=) |
| CN (1) | CN102753162A (https=) |
| AU (2) | AU2010310515B2 (https=) |
| BR (1) | BR112012009423A2 (https=) |
| CA (1) | CA2779282C (https=) |
| DK (1) | DK2490684T3 (https=) |
| ES (1) | ES2659353T3 (https=) |
| PL (1) | PL2490684T3 (https=) |
| PT (1) | PT2490684T (https=) |
| RU (1) | RU2549954C2 (https=) |
| WO (1) | WO2011050302A2 (https=) |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2888811C (en) * | 2012-10-22 | 2023-10-24 | University Of Southern California | A diet package, and uses thereof |
| CN114236130A (zh) * | 2013-02-12 | 2022-03-25 | 南加利福尼亚大学 | 用于减轻年龄相关症状的膳食包装 |
| US9386790B2 (en) * | 2013-07-01 | 2016-07-12 | University Of Southern California | Fasting condition as dietary treatment of diabetes |
| US10172839B2 (en) | 2014-03-06 | 2019-01-08 | University Of Southern California | Use of short term starvation regimen in combination with kinase inhibitors to enhance traditional chemo-drug efficacy and feasibility and reverse side effects of kinases in normal cells and tissues |
| WO2015134837A2 (en) * | 2014-03-06 | 2015-09-11 | University Of Southern California | Use of short term starvation regimen in combination with kinase inhibitors to enhance traditional chemo-drug efficacy and feasibility and reverse side effects of kinases in normal cells and tissues |
| CA2944088C (en) * | 2014-03-28 | 2022-06-21 | L-Nutra Inc. | Tyrosine kinase inhibitors for use in a method of treating cancer in association with a reduced caloric intake |
| EP3125904A4 (en) * | 2014-04-02 | 2017-08-30 | University of Southern California | Autoimmunity and multiple sclerosis treatment |
| KR20180002677A (ko) * | 2015-04-16 | 2018-01-08 | 유니버시티 오브 써던 캘리포니아 | 라파마이신 및 덱사메타손에 의해 유도된 표준 및 고 글루코스 조건에 대응하여 정상 세포를 보호하고 암 감작 조건을 생성하는 금식 모방 규정식(fmd) 및 글루코스 저하 약물 |
| BR112017023748A2 (pt) | 2015-05-06 | 2018-07-31 | University Of Southern California | métodos para tratar hipertensão; reduzir níveis de colesterol elevados e/ou níveis de ldl elevados; reduzir níveis de triglicerídeo elevados e/ou níveis de crp elevados; tratar um indivíduo com níveis de insulina ou glicose elevados; tratar obesidade abdominal; tratar um indivíduo com níveis de igf-1 elevados; tratar ou prevenir inflamação; aumentar regeneração; e reduzir fígado gorduroso |
| RU2018114459A (ru) * | 2015-09-21 | 2019-10-23 | Ифом Фондационе Иституто Фирк Ди Онколоджа Молеколаре | Новые стратегии лечения рака крови |
| CN108463121A (zh) * | 2016-01-12 | 2018-08-28 | 南加利福尼亚大学 | 长期禁食模仿作为多发性骨髓瘤和其它癌症的膳食治疗的用途 |
| KR20180120153A (ko) | 2016-02-15 | 2018-11-05 | 유니버시티 오브 써던 캘리포니아 | 당뇨병 및 기타 질환 치료를 위한 배아형 재생을 자극하는 약물 조합물 및 방법 |
| US12042477B2 (en) * | 2016-02-23 | 2024-07-23 | Cancer Research Technology Limited | Dietary product devoid of at least two non essential amino acids |
| AU2017261723B2 (en) | 2016-05-11 | 2023-02-09 | University Of Southern California | Fasting mimicking diet (FMD) as an immunoregulatory treatment for gastrointestinal autoimmune/inflammatory diseases. |
| IT201700008499A1 (it) * | 2017-01-26 | 2018-07-26 | Univ Degli Studi Genova | Composizione dietetica per la prevenzione e/o il trattamento dell’iperplasia dell’endometrio |
| US11284640B2 (en) | 2017-02-14 | 2022-03-29 | University Of Southern California | Fasting mimicking diet |
| CN107951892A (zh) * | 2018-01-19 | 2018-04-24 | 丽水学院 | 锌原卟啉在制备增强人结直肠癌细胞对5-氟尿嘧啶化疗敏感性药物中的应用 |
| MX2020009613A (es) | 2018-03-15 | 2021-02-26 | Univ Southern California | Dieta que imita el ayuno (fmd) pero no ayuno solo con agua, promueve la reversion de la inflamacion y patologia de la enfermedad de intestino irritable (ibd). |
| WO2020015842A1 (en) * | 2018-07-18 | 2020-01-23 | Michalsen Andreas | Effects of a short-term fasting mimicking diet on quality of life and tolerance to chemotherapy in patients with cancer |
| CA3119100C (en) | 2018-11-09 | 2024-06-04 | Valter D. Longo | Nutrition bar for intermittent fasting-mimicking |
| CA3134756A1 (en) | 2019-04-30 | 2020-11-05 | Valter D. Longo | Fasting-mimicking diet (fmd) as an intervention for alzheimer's disease (ad) |
| JP6747702B1 (ja) * | 2019-05-10 | 2020-08-26 | 株式会社医療情報技術研究所 | 栄養処方管理システム |
| PH12021552866A1 (en) | 2019-05-14 | 2022-11-07 | Tyme Inc | Compositions and methods for treating cancer |
| IT201900009954A1 (it) * | 2019-06-24 | 2020-12-24 | Fondazione Irccs Istituto Naz Dei Tumori | Preparazione alimentare a basso contenuto calorico per l’alimentazione di pazienti affetti da neoplasie |
| WO2021118324A1 (ko) * | 2019-12-13 | 2021-06-17 | 서울대학교산학협력단 | 암의 예방 또는 치료용 약학 조성물 |
| IT202000007153A1 (it) | 2020-04-03 | 2021-10-03 | Ifom Fondazione St Firc Di Oncologia Molecolare | Apporto calorico ridotto e immunoterapia per il trattamento del cancro |
| US10905698B1 (en) | 2020-05-14 | 2021-02-02 | Tyme, Inc. | Methods of treating SARS-COV-2 infections |
| US12220402B2 (en) | 2020-06-03 | 2025-02-11 | Faeth Therapeutics, Inc. | Formulations for personalized methods of treatment |
| WO2021247923A1 (en) | 2020-06-04 | 2021-12-09 | Faeth Therapeutics, Inc. | Personalized methods of treating cancer |
| TW202227113A (zh) * | 2020-12-01 | 2022-07-16 | 南加州州立大學 | 模擬禁食飲食提升急性淋巴母細胞白血病模型中的無癌存活 |
| US20240000125A1 (en) * | 2020-12-17 | 2024-01-04 | Fondazione Irccs Istituto Nazionale Dei Tumori | Diet preparation for the nutrition of cancer patients with a restricted calorie intake |
| EP4066823B1 (en) | 2021-03-30 | 2025-04-30 | IFOM - Istituto Fondazione di Oncologia Molecolare ETS | Reduced caloric intake and anticancer agents for the treatment of cancer |
| CN115590963A (zh) * | 2022-07-13 | 2023-01-13 | 复旦大学（Cn） | 酮体、酮体诱导剂和生酮组合物中的至少一种在治疗和/或预防血小板减少症药物中的应用 |
| EP4599826A1 (en) | 2024-02-06 | 2025-08-13 | IFOM - Istituto Fondazione di Oncologia Molecolare ETS | Leucine for use in the treatment of cancer |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2074731C1 (ru) * | 1994-12-29 | 1997-03-10 | Игорь Александрович Бойко | Фитокомплекс, обладающий противоопухолевым действием, и способ лечения онкологических больных |
| CN1315473C (zh) * | 1997-03-17 | 2007-05-16 | 英国技术集团国际有限公司 | 治疗组合物 |
| AU5319499A (en) * | 1999-07-22 | 2001-02-13 | Ivan L. Cameron | Fatty acids to minimize cancer therapy side effects |
| JP4625156B2 (ja) * | 2000-04-10 | 2011-02-02 | イーエヌ大塚製薬株式会社 | 癌化学療法に伴う副作用軽減剤 |
| WO2005117542A2 (en) * | 2004-05-10 | 2005-12-15 | Novacea, Inc. | Treatment of pancreatic cancer with active vitamin d compounds in combination with other treatments |
| WO2006043966A2 (en) * | 2004-10-15 | 2006-04-27 | University Of Tennessee Research Foundation | Methods for inducing apoptosis in adipocytes |
| US20070116802A1 (en) * | 2005-11-23 | 2007-05-24 | Carl Germano | High quality caloric composition |
| US20080038367A1 (en) * | 2006-08-11 | 2008-02-14 | Sal Saloum | Nutritional supplement compositions and methods of preparing |
| RU2354369C2 (ru) * | 2007-03-16 | 2009-05-10 | Михаил Владимирович Кутушов | Применение родамина 6ж в качестве лекарственного средства для лечения злокачественных новообразований и амилоидозов |
| EP2156188B1 (en) * | 2007-03-28 | 2021-05-05 | University of Southern California | Induction of differential stress resistance and uses thereof |
| CA2706656A1 (en) * | 2007-11-26 | 2009-06-04 | Nestec S.A. | Compositions and methods for inhibiting the activation of dsrna-dependent protein kinase and tumor growth inhibition |
-
2010
- 2010-10-22 CA CA2779282A patent/CA2779282C/en active Active
- 2010-10-22 CN CN2010800560747A patent/CN102753162A/zh active Pending
- 2010-10-22 DK DK10825771.8T patent/DK2490684T3/en active
- 2010-10-22 EP EP10825771.8A patent/EP2490684B1/en active Active
- 2010-10-22 WO PCT/US2010/053821 patent/WO2011050302A2/en not_active Ceased
- 2010-10-22 ES ES10825771.8T patent/ES2659353T3/es active Active
- 2010-10-22 PT PT108257718T patent/PT2490684T/pt unknown
- 2010-10-22 JP JP2012535426A patent/JP2013508411A/ja active Pending
- 2010-10-22 RU RU2012118588/15A patent/RU2549954C2/ru active
- 2010-10-22 US US12/910,508 patent/US20110118528A1/en not_active Abandoned
- 2010-10-22 AU AU2010310515A patent/AU2010310515B2/en active Active
- 2010-10-22 PL PL10825771T patent/PL2490684T3/pl unknown
- 2010-10-22 BR BR112012009423A patent/BR112012009423A2/pt not_active Application Discontinuation
-
2016
- 2016-03-11 AU AU2016201607A patent/AU2016201607B2/en active Active
-
2021
- 2021-03-17 US US17/204,419 patent/US20210209516A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2010310515A1 (en) | 2012-05-17 |
| EP2490684B1 (en) | 2018-01-03 |
| JP2013508411A (ja) | 2013-03-07 |
| US20110118528A1 (en) | 2011-05-19 |
| PT2490684T (pt) | 2018-04-02 |
| US20210209516A1 (en) | 2021-07-08 |
| ES2659353T3 (es) | 2018-03-14 |
| BR112012009423A2 (pt) | 2017-06-13 |
| RU2012118588A (ru) | 2013-11-27 |
| AU2016201607A1 (en) | 2016-03-31 |
| RU2549954C2 (ru) | 2015-05-10 |
| PL2490684T3 (pl) | 2018-07-31 |
| DK2490684T3 (en) | 2018-04-09 |
| EP2490684A4 (en) | 2016-05-04 |
| WO2011050302A3 (en) | 2011-08-25 |
| AU2016201607B2 (en) | 2017-11-30 |
| CA2779282A1 (en) | 2011-04-28 |
| WO2011050302A2 (en) | 2011-04-28 |
| AU2010310515B2 (en) | 2016-01-07 |
| CN102753162A (zh) | 2012-10-24 |
| EP2490684A2 (en) | 2012-08-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20210209516A1 (en) | Methods and Nutritional Formulations to Increase the Efficacy and Reduce the Side Effects of Cancer Treatment | |
| Miyata et al. | Randomized study of clinical effect of enteral nutrition support during neoadjuvant chemotherapy on chemotherapy-related toxicity in patients with esophageal cancer | |
| AU2020200726B2 (en) | Use of short term starvation regimen in combination with kinase inhibitors to enhance traditional chemo-drug efficacy and feasibility and reverse side effects of kinases in normal cells and tissues | |
| RU2734774C2 (ru) | Рацион, имитирующий воздержание от пищи (fmd), и лекарственные средства, снижающие уровень глюкозы, защищают нормальные клетки и создают условия сенсибилизации при раке в ответ на стандартные условия и условия с высоким содержанием глюкозы, индуцированные рапамицином и дексаметазоном | |
| US20150250771A1 (en) | Use of short term starvation regimen in combination with kinase inhibitors to enhance traditional chemo-drug efficacy and feasibility and reverse side effects of kinases in normal cells and tissues | |
| JP2021183622A (ja) | 多発性骨髄腫及び他のがんに対する食事療法としての長期断食模倣の使用 | |
| US20240358769A1 (en) | Compositions and Methods for Treating Inflammation Associated with IL-6 | |
| JP2023551730A (ja) | 断食模倣食は、急性リンパ芽球性白血病モデルにおける無がん生存を促進する | |
| HK1233488B (en) | Use of short term starvation regimen in combination with kinase inhibitors to enhance traditional chemo-drug efficacy and feasibility and reverse side effects of kinases in normal cells and tissues | |
| Tan | Why Do Cancer Patients Take More Vitamins? | |
| Bussink | The role of nutrition on effectiveness of chemotherapy |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20150902 |
|
| MPN | Maintenance fee for patent paid |
Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 14TH ANNIV.) - STANDARD Year of fee payment: 14 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20241018 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20241018 Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20241018 |
|
| MPN | Maintenance fee for patent paid |
Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 15TH ANNIV.) - STANDARD Year of fee payment: 15 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20251017 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20251017 |